Life Sciences Archive » July, 2009

Life Sciences - July, 2009

149 articles

• Judge Hits Reset Button In Cephalon Antitrust Actions
• EPA Reaches Deal With Disinfectant Maker
• Novartis Bests Defect Claims In Trileptal Suit
• Q&A With Troutman Sanders' Barry Brett
• Insurer's Class Action Over Trasylol Dismissed
• Pfizer Finalizes $75M Trovan Deal With Nigeria
• Women GCs Climb Ranks But Still Face Challenges
• FTC Fights To Block Thoratec, HeartWare Merger
• Abbott Yanks Potentially Lethal Coronary Catheters
• 1st Case To Go To Trial In Neurontin MDL Dropped
• Male Enhancement, Bodybuilding Products Recalled
• Merck Sells Merial Stake For $4B To Expedite Merger
• Abbott Appeals $29.2M C&D Pregnancy Test Verdict
• Q&A With Sheppard Mullin's Amar Thakur
• FDA Says Bodybuilding Products Contain Steroids
• Doctor Hides Ties To Medtronic At Senate Hearing
• FDA To List Mercury Dental Fillings As Moderate Risk
• Analyzing The EC's Drug Sector Inquiry Report
• Apotex Asks High Court To Hear Plavix Dispute
• KV Pharmaceutical Moves To Toss Securities Action
• Baby Formula Suit Against Abbott Survives
• FTC, Cephalon Must Refile Antitrust Motions: Judge
• Baxter Settles Ill. Drug Price Fraud Suit For $6.8M
• Merck's Bid To Block Expert Testimony Mostly Fails
• Tafas V. Doll Could Become Moot: USPTO, GSK, Tafas
• Medtronic To Pay Abbott $400M To Quell Stent Suits
• Medarex Investor Sues Over $2B Bristol-Myers Sale
• Pfizer Sets $75M Trovan Deal In Stone
• Lilly Allowed To Keep Expert Out Of Prozac Death Suit
• Wyeth's 'Medical Ghostwriting' Docs To See Daylight
• Merck, Schering Settle Investor Action Over Merger
• Yaz, Yasmin Plaintiffs Appeal To JPMDL
• USPTO Confirms KCI Wound Therapy Patents
• NY Latest To Challenge $55M Schering Deal
• New Complaint Allowed In AstraZeneca Pain Med Suit
• Teva Settles Patent Spat Over Ortho Tri-Cyclen
• Bristol-Myers Settles Plavix Securities Suit For $125M
• Digitek Judge Allows Contact With Actavis Workers
• Cordis Loses Motion For Judgment In Stent IP Case
• U. Of Pittsburgh Wins Fight Over Stem Cell Patent
• Mass. Balks At $55M Schering Price Inflation Deal
• Ohio Asst. Managers Slap Rite Aid With Overtime Suit
• Bristol-Myers To Purchase Medarex For $2.1B
• Case Over Lilly's Zyprexa Gets Booted For 2nd Time
• FDA Warns Abbott About Marketing Of HIV Drug
• Troutman Adds 5 IP Attys To New Life Sciences Team
• Invacare Sues Rival Over Hospital Bed Patents
• SEC Hits Perry With Merger Arbitrage Fine
• Lundbeck Fails To Escape NeoProfen Antitrust Suits
• Health Fund's Seroquel Complaint Booted
• Two Execs Plead Guilty In Bone Cement Deaths Case
• Solvay, Watson Say AndroGel Deals Are Legal
• Claims Survive In Citrucel Suit
• Medtronic Unit Gets $2M In Spine Surgery Patent Suit
• Plaintiffs Win Again In Seroquel MDL Experts Fight
• NM Wins Bid To Return Seroquel Suit To State Court
• Investors Sue Caraco Over Plant Inspections, Raids
• Matrixx Hit With Shareholder Action Over Zicam
• How The Supreme Court Should Resolve Bilski
• EU Approves Pfizer, Wyeth Deal With Conditions
• EU Targets Energy, Tech, Drugs For Antitrust Action
• Pro-Pharmaceuticals Shakes Off Trade Secret Claims
• $36M Trade Secrets Verdict Rushes Luna Into Ch. 11
• Young You Recalls Diet Pills Containing Sibutramine
• Inferring Intent In Inequitable Conduct Cases
• Teva Yanks Tainted Lots Of Anesthetic Propofol
• Genzyme Targets Sandoz Over Hectorol Patent
• FDA Launches Safety Review Of Asthma Drug Xolair
• Mannatech Sues Rivals Over Diet Supplement Patents
• The FDA's Approval Of Percocet And Vicodin
• Plaintiffs' Experts Nixed In Bausch ReNu Case
• Democratic Senators Rip Health Insurance Industry
• Male Enhancement Pills Containing ED Drugs Recalled
• The Risks Of Online Auctions, Counterfeit Goods
• AstraZeneca Wants Scope Narrowed In Seroquel MDL
• Merck, Schering-Plough End Vytorin Investigation
• Male Enhancement Pills With Tadalafil Face Recall
• Trasylol Plaintiffs Step Up Fight To See Bayer Report
• Dosage Issue Spurs Recall Of Acetaminophen Drops
• KCI Loses UK Wound-Patent Fight To Smith & Nephew
• Sens. Settle On 12-Year Exclusivity For Biologics
• Off-Label Marketing Claims Against Schering Tossed
• Inola Loses Bid To Revive Express Scripts Case
• Appeal Set For Thwarted Seroquel Plaintiff
• FDA Requires Labeling Changes For Transplant Drugs
• 3rd Circ. Affirms FDA Ban On Ephedrine Products
• Device Makers Engaged In Off-Label Scheme: Suits
• Sen. Committee Ups Health Care Fraud Penalties
• Albion, Lannett End Generic Vitamin Spat
• Bayer Hit With Injury, Death Suits Over Yaz, Yasmin
• Travelers Must Fund Heparin Defense: Equity Firm
• Viagra MDL Judge Bars Expert From Daubert Hearing
• Sandoz Loses Bid For Attys' Fees In Lovenox Spat
• Watson Pharma Ala. AWP Case Ends In Mistrial
• Counsel Fees Cut In Warner Chilcott Securities Action
• Aspirin Marketing MDL Bears Down on Bayer
• Everett, Breckenridge Reach Deal In Vitamin Suits
• Medtronic Pulls Insulin Infusion Sets
• Roxane Wants DOJ Sanctioned For Spoliation
• Covidien Recalls Weak Batch Of Diagnostic Agent
• Purdue Must Face Alpharma OxyContin Patent Claims
• Sun, Forest Reach Deal In Lexapro Patent Suit
• US Docs Kept Back In ObTape Discovery Dispute
• Ebewe, Sanofi Come To Terms Over Eloxatin Patent
• C&D Denied Fees In $29M Abbott Pregnancy Test Suit
• Canadian Federal Court Deals Blow To Pfizer
• The FTC's Stance On Generic Biologics
• Lawmakers Seek Info On Medtronic Adviser Probe
• Kennedy Adds To List Of Follow-On Biologics Bills
• 9th Circ. Kills Injunction On Sale Rules For Plan B
• Amgen, Immunex Settle Ill. AWP Case For $7.8M
• EU Report Announces Drugmaker Probes Over Deals
• Injunction Denied In Tyco Trachea Tube Patent Case
• Zicam Lawsuits Pile Up In FDA Warning's Wake
• CCS Medical Files For Ch. 11 With Prearranged Plan
• Fed. Circ. To Reconsider Tafas V. Doll
• 9th Circ. Says No Claim Stated In Norvir Pricing Case
• EU To Reveal Antitrust Cases Against Drugmakers
• FDA Orders Stronger Warning For Propoxyphene
• Flonase Antitrust Claims Survive GSK's Dismissal Bid
• Chantix Wrongful Death Suit Survives Bid To Toss
• Galderma Hits Lupin With Rosacea Drug Patent Suit
• Wyeth Heads To Court Again To Protect Effexor
• Genzyme Takes On Sandoz Over Renagel ANDA
• Takeda Sues Torrent Over Diabetes Drug Patents
• UK Court Clarifies Obviousness Rule In Levaquin Suit
• Immucor, J&J Face Another Antitrust Class Action
• 'Reverse Payments' Presumptively Unlawful: DOJ
• Seroquel Clinicians' Sexcapades Fair Game In MDL
• Sanofi Loses Bid To Stay Launch Of Generic Eloxatin
• Novartis Loses Glivec Patent Fight In India
• Wyeth Wins Sanctions Against Firm In Prempro MDL
• Guidant Judge Rejects 3rd Party Payor Claims Again
• Sotomayor's Approach To Antitrust
• Apotex Launches Suit Over Eisai's Aricept Patents
• Last Acculink Claim Against Abbott Nixed
• Expanded Discovery Allowed In Actavis Digitek MDL
• SF Health Plan Seeks Class Cert. In McKesson AWP Suit
• 9th Circ. Vacates Marlyn Supplement Recall Order
• NLRB Erred In Nursing Home Case Ruling: DC Circ.
• Alzheimer's Institute Sues Pfizer Over Mice Patents
• Howrey Absorbs IP Litigation Boutique Day Casebeer
• FDA Mandates Labels For Pfizer, GSK Smoker Drugs
• Forest, Lundbeck Lose Bid To Limit Lexapro Claims
• Bayer Hits Teva With Suit Over Levitra Patent
• FDA Panel Pushes Acetaminophen Painkiller Ban
• Ohio Court Says Law Bars Off-Label Abortion Pill Uses
• Eli Lilly Wins Dismissal Of Another Zyprexa Case
• Q&A With Kirkland & Ellis' Luke Dauchot